Praxis Precision Medicines

Home
United States
Boston, MA
Praxis Precision Medicines

Praxis has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of th

erapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Our mission is to help patients by delivering life-altering treatments faster and more effectively than has ever been done before – and to do it again and again. We pursue the development of candidates that address the treatment needs of patients, caregivers and the treating community, including targeting the underlying disease pathology versus just symptom management. We intend to develop therapies that provide patients long-term relief from their disorders and significantly reduce the overall burden to patients and caregivers.

05/28/2026

May is Mental Health Awareness Month. Essential Tremor can have an impact on a person’s emotional well-being. If you’re living with ET, and are having a hard time coping, check out these helpful strategies from our friends at the International Essential Tremor Foundation.

Their worksheet includes ideas to deal with stress and make daily tasks more manageable: https://bit.ly/3XDwh3J

At Praxis, we are committed to advancing care for people with ET. Learn more about our work at https://www.praxisessentialtremor.com

05/26/2026

The science brought Lauren to Praxis. The patients made it personal.

When Lauren joined in 2018, she was drawn in by the breadth of the pipeline and the team's ability to translate genetics into CNS drug discovery. A company with multiple assets, real scientific flexibility and a compelling vision for what precision medicine could do for patients.

But there was something else. Lauren had epilepsy as a child. The patients Praxis is working to help aren't abstract to her. They never have been.

That kind of connection runs deep at Praxis. It shows up in how we work, why we stay and what we're building toward.

Join our team: https://praxismedicines.com/

05/14/2026

Did you know Essential Tremor is the most common movement disorder? An estimated 7 million people in the U.S. live with ET—that’s 8 times more than those with Parkinson’s.

“I want other people with ET to know that they aren’t alone. Parkinson’s disease gets talked about more than ET, and yet, far more people have ET.” – Allison, living with ET

It’s time to raise awareness. Let’s spread the word.

To learn more and explore ET community stories and resources visit: https://www.praxisessentialtremor.com.

04/23/2026

is not “just a tremor.” It can deeply impact daily life, emotional well-being, and independence.

“I wish more people understood the impact of ET – it affects you mentally, emotionally, socially and physically.” – Barbara, living with ET

It’s time to raise awareness. Let’s spread the word.

To learn more and explore ET community stories and resources visit: https://www.praxisessentialtremor.com.

04/14/2026

Praxis Precision Medicines has announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application for ulixacaltamide HCl for the treatment of essential tremor (ET) in adults, with a PDUFA target action date of January 29, 2027.

We are encouraged by this important milestone as we continue our work to advance an investigational therapy for patients living with essential tremor.

Read the full press release: https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-fda-acceptance-new-drug

04/06/2026

Praxis Precision Medicines today announced positive topline results from the EMBRAVE Part A trial of elsunersen in pediatric patients with SCN2A early-onset developmental and epileptic encephalopathy (DEE).

In the study, elsunersen demonstrated a 77% placebo-adjusted reduction in seizure frequency, with additional improvements observed across measures including sleep, motor function, muscle tone, and attention.

These findings support the continued development of elsunersen as a potential therapy for patients with SCN2A-related DEEs, as we advance our broader pipeline of precision neuroscience therapies.

Read the full announcement: https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-results-embrave

03/31/2026

Praxis Precision Medicines has announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its New Drug Application for relutrigine for the treatment of SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), with a PDUFA target action date of September 27, 2026.

We are encouraged by this important milestone as we continue our work to advance a potential new treatment option for patients and families affected by these severe genetic epilepsies.

Read the full press release: https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-fda-acceptance-and-priority

03/26/2026

ICYMI: At our November 2025 All Hands, Praxons wore purple in support of the epilepsy community 💜

That day also included hands-on seizure first aid training and assembling newly diagnosed kits in partnership with the Epilepsy Foundation of New England. It was a meaningful reminder of the importance of showing up for patients and families beyond the lab.

Today, on , we stand with people living with epilepsy, their families, and the advocates and researchers working to deepen understanding of this condition.

At Praxis, advancing science for people living with CNS disorders drives our work every day.

03/24/2026

As Essential Tremor Awareness Month continues, we are taking time to recognize the impact of essential tremor.

Essential tremor is one of the most common movement disorders, yet its impact on daily life is often underestimated. At Praxis, advancing research in serious neurologic disorders, including essential tremor, is central to our mission. The lived experiences of people with essential tremor shape how we think about unmet need and the urgency behind our work.

Through More Than Tremor, we share stories from individuals in the ET community — perspectives that help inform and inspire our research. Explore these personal experiences and hear directly from people living with essential tremor: https://www.praxisessentialtremor.com/more-than-tremor/

03/17/2026

A new clinical trial is evaluating a potential treatment for adults with epilepsy. You could participate from the comfort of your home. See if you qualify today: https://bit.ly/4utfnmZ

Address

99 High Street, 30th Floor
Boston, MA
02110

Website

https://praxismedicines.com/, https://www.praxisessentialtremor.com/, https://frugalbookstore.net/collections/raising-a-

Alerts

Be the first to know and let us send you an email when Praxis Precision Medicines posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

In A Minute Security Services
459 Broadway Suite B3, Everett

Want your business to be the top-listed Business in Boston?